0000000000772591

AUTHOR

S. Dastoli

showing 2 related works from this author

Physician–patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, pros…

2017

Background: Patients with multiple actinic keratoses (AKs) should be treated with field-directed therapy. Such treatments challenge patients’ adherence due to out-of-pocket costs, length of treatment and severity of local skin reactions (LSRs). Effective physician–patient communication (PPC) may buffer therapy-related distress, thus improving quality of life, treatment satisfaction and adherence. Objectives: We evaluated the interplay between PPC, LSR intensity (safety) and lesion clearance rates (effectiveness) on treatment satisfaction, quality of life and treatment adherence among patients with multiple AKs receiving topical field-directed therapies. Methods: In this observational, multi…

Male2708; infectious diseases; actinic keratosesDiclofenacActinictopical field‐directed therapyAnti-Inflammatory AgentsAntineoplastic AgentsAdministration CutaneousMedication AdherenceAdministration Cutaneous; Aged; Aged 80 and over; Anti-Inflammatory Agents Non-Steroidal; Antineoplastic Agents; Diclofenac; Diterpenes; Drug Eruptions; Female; Humans; Imiquimod; Italy; Keratosis Actinic; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Communication; Medication Adherence; Patient Satisfaction; Physician-Patient Relationsactinic keratoses2708; Infectious Diseases80 and overHumansLongitudinal StudiesPatient Reported Outcome MeasuresProspective Studiesactinic keratoseAgedAged 80 and overPhysician-Patient RelationsImiquimodtreatmentCommunicationAnti-Inflammatory Agents Non-SteroidalKeratosisMiddle AgedKeratosis ActinicInfectious DiseasesCutaneousItalyPatient SatisfactionAdministrationQuality of LifeFemaleDrug EruptionsDiterpenesSettore MED/35 - MALATTIE CUTANEE E VENEREENon-Steroidal2708
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct